{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T04:33:16Z","timestamp":1792989196875,"version":"4.5.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015226","name":"Shengjing Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.critrevonc.2025.104831","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:23:48Z","timestamp":1752625428000},"page":"104831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Comparative efficacy of first-line therapies for PD-L1-negative advanced NSCLC: A network meta-analysis with reconstructed survival curves"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0979-7488","authenticated-orcid":false,"given":"Jie-Tao","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Qi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le-Tian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8391-6134","authenticated-orcid":false,"given":"Cheng-Bo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2025.104831_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104831_bib2","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-line immunotherapy for non-small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104831_bib3","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104831_bib4","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104831_bib5","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus Chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104831_bib6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jamaoncol.2023.5258","article-title":"Atezolizumab and platinum plus pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer: a phase 3 randomized clinical trial","volume":"10","author":"Shiraishi","year":"2024","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104831_bib7","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104831_bib8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","article-title":"Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104831_bib9","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jtho.2022.09.109","article-title":"Predictive biomarkers for immunotherapy in lung cancer: perspective from the international association for the study of lung cancer pathology committee","volume":"17","author":"Mino-Kenudson","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104831_bib10","article-title":"Advances and prospects of biomarkers for immune checkpoint inhibitors","volume":"5","author":"Yamaguchi","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104831_bib11","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104831_bib12","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.jtho.2021.06.019","article-title":"Updated overall survival analysis from impower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC","volume":"16","author":"Jassem","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"10183","key":"10.1016\/j.critrevonc.2025.104831_bib13","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104831_bib14","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score \u2265 1% in the KEYNOTE-042 study","volume":"41","author":"de Castro","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10274","key":"10.1016\/j.critrevonc.2025.104831_bib15","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104831_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221105024","article-title":"Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression \u226550","volume":"14","author":"Freemantle","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104831_bib17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1186\/s12885-023-11285-4","article-title":"Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression\u2009\u2265\u200950","volume":"23","author":"Chen","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104831_bib18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41379-021-00932-5","article-title":"Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer","volume":"35","author":"Sholl","year":"2022","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104831_bib19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12943-018-0864-3","article-title":"Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors","volume":"17","author":"Yi","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104831_bib20","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.lungcan.2017.08.005","article-title":"PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review","volume":"112","author":"Brody","year":"2017","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104831_bib21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11864-020-00768-2","article-title":"Immunotherapy alone or in combination with chemotherapy as first-line treatment of non-small cell lung cancer","volume":"21","author":"Saxena","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104831_bib22","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.22.01503","article-title":"Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227","volume":"41","author":"Brahmer","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104831_bib23","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1200\/JCO.22.00727","article-title":"Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: a multicenter randomized phase III trial (CHOICE-01)","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104831_bib24","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial","volume":"28","author":"Gogishvili","year":"2022","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104831_bib25","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104831_bib26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","article-title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial","volume":"9","author":"Zhou","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104831_bib27","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodr guez-Abreu","year":"2021","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104831_bib28","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jtho.2020.07.014","article-title":"Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (oncology pRogram by InnovENT anti-PD-1-11)","volume":"15","author":"Yang","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104831_bib29","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jtho.2021.05.005","article-title":"Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial","volume":"16","author":"Lu","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104831_bib30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(23)00431-9","article-title":"First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial","volume":"12","author":"Zhong","year":"2024","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104831_bib31","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial","volume":"17","author":"Ren","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104831_bib32","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-Year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104831_bib33","article-title":"Pembrolizumab plus chemotherapy for chinese patients with metastatic squamous NSCLC in KEYNOTE-407","volume":"2","author":"Cheng","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104831_bib34","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","article-title":"Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12)","volume":"16","author":"Zhou","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104831_bib35","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104831_bib36","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S1470-2045(21)00650-1","article-title":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104831_bib37","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study","volume":"41","author":"Johnson","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104831_bib38","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104831_bib39","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/cam4.5144","article-title":"Results from the IMpower132 China cohort: atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer","volume":"12","author":"Lu","year":"2023","journal-title":"Cancer Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104831_bib40","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial","volume":"15","author":"Jotte","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104831_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100273","article-title":"First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update","volume":"6","author":"Reck","year":"2021","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104831_bib42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jtho.2022.09.223","article-title":"NEPTUNE: phase 3 study of first-line durvalumab plus tremelimumab in patients with metastatic NSCLC","volume":"18","author":"de Castro","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104831_bib43","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jtho.2021.10.023","article-title":"CCTG BR34: a randomized phase 2 trial of durvalumab and tremelimumab with or without platinum-based chemotherapy in patients with metastatic NSCLC","volume":"17","author":"Leighl","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104831_bib44","doi-asserted-by":"crossref","first-page":"17061","DOI":"10.1002\/cam4.6348","article-title":"First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52\/TASUKI-52 randomized controlled trial","volume":"12","author":"Kim","year":"2023","journal-title":"Cancer Med."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104831_bib45","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104831_bib46","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104831_bib47","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1002\/cncr.33142","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: a pooled analysis of 3 randomized controlled trials","volume":"126","author":"Borghaei","year":"2020","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.critrevonc.2025.104831_bib48","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2217\/imt-2023-0043","article-title":"Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in Asia","volume":"15","author":"Cheng","year":"2023","journal-title":"Immunotherapy"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104831_bib49","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41571-021-00520-1","article-title":"Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC","volume":"18","author":"Grant","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104831_bib50","article-title":"Comparative efficacy of immune checkpoint inhibitors combined with chemotherapy in patients with advanced driver-gene negative non-small cell lung cancer: A systematic review and network meta-analysis","volume":"10","author":"Zhang","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.critrevonc.2025.104831_bib51","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104831_bib52","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1111\/1759-7714.14664","article-title":"Immunotherapy combined with chemotherapy versus chemotherapy alone as the first-line treatment of PD-L1-negative and driver-gene-negative advanced nonsquamous non-small-cell lung cancer: An updated systematic review and meta-analysis","volume":"13","author":"Chai","year":"2022","journal-title":"Thorac. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104831_bib53","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2217\/imt-2021-0208","article-title":"First-line chemoimmunotherapy versus chemotherapy in PD-L1-negative patients with non-small-cell lung cancer","volume":"14","author":"Mengato","year":"2022","journal-title":"Immunotherapy"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104831_bib54","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/1744666X.2022.2088510","article-title":"Efficacy comparison of immune treating strategies for NSCLC patients with negative PD-L1 expression","volume":"18","author":"Ding","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104831_bib55","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00432-019-03070-3","article-title":"First-line PD-1\/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or\u2009< 1% PD-L1-expressing metastatic non-small-cell lung cancers","volume":"146","author":"Landre","year":"2020","journal-title":"J. Cancer Res Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104831_bib56","doi-asserted-by":"crossref","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104831_bib57","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for Scoping Reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104831_bib58","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"10066","key":"10.1016\/j.critrevonc.2025.104831_bib59","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104831_bib60","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-021-00431-4","article-title":"Programmed death ligand 1 signals in cancer cells","volume":"22","author":"Kornepati","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104831_bib61","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","article-title":"Overcoming resistance to tumor-targeted and immune-targeted therapies","volume":"11","author":"Aldea","year":"2021","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104831_bib62","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104831_bib63","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","article-title":"Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation","volume":"15","author":"Wu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104831_bib64","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","article-title":"Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer","volume":"17","author":"Cheng","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"45","key":"10.1016\/j.critrevonc.2025.104831_bib65","doi-asserted-by":"crossref","first-page":"22699","DOI":"10.1073\/pnas.1821218116","article-title":"Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies","volume":"116","author":"Wei","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104831_bib66","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104831_bib67","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104831_bib68","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2020.04.009","article-title":"Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: do they have a role in non-oncogene-addicted non-small cell lung cancer?","volume":"144","author":"Popat","year":"2020","journal-title":"Lung Cancer"},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104831_bib69","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.3390\/molecules25173900","article-title":"Interaction between immunotherapy and antiangiogenic therapy for cancer","volume":"25","author":"Furukawa","year":"2020","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104831_bib70","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41392-022-01130-8","article-title":"The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104831_bib71","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41698-021-00248-2","article-title":"Multimodal analysis suggests differential immuno-metabolic crosstalk in lung squamous cell carcinoma and adenocarcinoma","volume":"6","author":"Leitner","year":"2022","journal-title":"NPJ Precis Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104831_bib72","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jtho.2017.03.010","article-title":"Lung adenocarcinoma and squamous cell carcinoma gene expression subtypes demonstrate significant differences in tumor immune landscape","volume":"12","author":"Faruki","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104831_bib73","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/jnci\/djae053","article-title":"Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer","volume":"116","author":"Nagasaki","year":"2024","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104831_bib74","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005573","article-title":"Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types","volume":"10","author":"Maule","year":"2022","journal-title":"J. Immunother. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:46:22Z","timestamp":1792986382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825002197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":74,"alternative-id":["S1040842825002197"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104831","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy of first-line therapies for PD-L1-negative advanced NSCLC: A network meta-analysis with reconstructed survival curves","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104831","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104831"}}